Immucell Corp
Veridion Score
Composite trend over time
Why is ICCC moving today?
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ICCC.
ICCC insider activity
Immucell Corp
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ICCC.
ICCC contract awards, year to date.
Public federal awards linked to this ticker.
ICCC lobbying filings, year to date.
Registered lobbying filings matched to Immucell Corp.